Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / BOLT - Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies

BOLT - Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies

Bolt Biotherapeutics Inc.
  • Bolt has built out a next-generation immunotherapy platform to design biologics for cancers that are not accessible for the current standard-of-care.
  • The company's lead asset, BDC-1001, is expected to complete phase 1 clinical trials later this year creating a window for an opportunistic investment.
  • As the pipeline matures, Bolt will be able to build out their partnerships and transition their business toward a fully-integrated diversified model.

For further details see:

Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies
Stock Information
Company Name: Bolt Biotherapeutics Inc.
Stock Symbol: BOLT
Market: NASDAQ
Website: boltbio.com
Menu
BOLT BOLT Quote BOLT Short BOLT News BOLT Articles BOLT Message Board
Get BOLT Alerts

News, Short Squeeze, Breakout and More Instantly...